Back to search results

Study on Incentives and Video Therapy for Latent Tuberculosis

This study is looking at new ways to help people complete treatment for latent tuberculosis (TB). Latent TB means you have the bacteria in your body but don't feel sick. The study will compare three approaches: usual care (getting your medication from the health department), Video Directly Observed Therapy (vDOT) alone (using a secure app to record yourself taking medication), and vDOT plus financial incentives. The financial incentives would decrease if you miss a dose. We want to see if the vDOT and financial incentives help more people finish their treatment for latent TB. You may be able to join if you are 18 or older, have latent TB, live in the Baltimore area, and speak English or Spanish. The study aims to enroll 399 participants.

Study design
This is an interventional study, meaning participants will receive specific treatments. It will involve up to 399 participants.
What's involved
Participants will receive medication in 30-60 day supplies. Some participants will also use a video app to record themselves taking medication.
Compensation
Financial incentives are offered to some participants, contingent on adherence verified by video DOT.
Follow-up
Treatment completion will be measured for up to 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05022862

Economic Incentives and vDOT for Latent Tuberculosis Infection

Recruiting
NAAges 18+InterventionalPrevention
Johns Hopkins University
~399 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Usual CareVideo Directly Observed Therapy aloneVideo Directly Observed Therapy plus Financial Incentives

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Treatment Completion
Measured over Up to 6 months

Conditions

Latent Tuberculosis

Explore related trials

Tuberculosis Infection

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Maunank Shah, MD, PhD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Principal Investigator
[email protected]
443-287-0401
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years old or older,
diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians
reside in Baltimore metro area
speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board
prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin

Exclusion

younger than 18 years old
diagnosed with active TB
prescribed an alternative treatment regimen for latent TB
pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated)
participant's spoken language does not have a translated long or short consent form

What this trial measures

  • Treatment CompletionUp to 6 months

    The primary outcome measure, completion of treatment for latent TB, will be assessed for all participants through MEMS caps. A participant will be considered to have completed treatment for study purposes if he/she takes 80% of the prescribed doses of medication, as determined by MEMS caps (i.e., 10 of 12 doses for participants prescribed weekly doses of rifapentine and isoniazid; 96 of 120 doses for participants prescribed daily doses of rifampin; 67 of 84 doses of daily isoniazid and rifampin